Hemogenyx Pharmaceuticals (LON:HEMO) Trading 3.3% Higher – Still a Buy?

Posted by on Jun 12th, 2026

Hemogenyx Pharmaceuticals Plc (LON:HEMO – Get Free Report) was up 3.3% on Thursday . The company traded as high as GBX 790.45 and last traded at GBX 790. Approximately 19,094 shares traded hands during mid-day trading, a decline of 33% from the average daily volume of 28,465 shares. The stock had previously closed at GBX 764.50.

Hemogenyx Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 167.66, a quick ratio of 6.72 and a current ratio of 1.38. The stock has a market capitalization of £53.72 million, a P/E ratio of -4.63 and a beta of 1.50. The firm has a 50-day moving average price of GBX 775.45 and a 200 day moving average price of GBX 788.95.

Hemogenyx Pharmaceuticals (LON:HEMO – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The company reported GBX (170.60) EPS for the quarter.

About Hemogenyx Pharmaceuticals

(Get Free Report)

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.

Featured Articles

Receive News & Ratings for Hemogenyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemogenyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.